Aurinia Pharmaceuticals (NASDAQ:AUPH) CEO Buys $3,147,756.40 in Stock

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) CEO Kevin Tang acquired 206,005 shares of Aurinia Pharmaceuticals stock in a transaction on Tuesday, June 2nd. The stock was purchased at an average price of $15.28 per share, with a total value of $3,147,756.40. Following the purchase, the chief executive officer owned 13,044,106 shares of the company’s stock, valued at $199,313,939.68. The trade was a 1.60% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Kevin Tang also recently made the following trade(s):

• On Monday, June 1st, Kevin Tang acquired 343,620 shares of Aurinia Pharmaceuticals stock. The stock was purchased at an average price of $15.28 per share, with a total value of $5,250,513.60.
• On Friday, May 29th, Kevin Tang acquired 264,981 shares of Aurinia Pharmaceuticals stock. The stock was purchased at an average price of $15.31 per share, with a total value of $4,056,859.11.

Aurinia Pharmaceuticals Price Performance

Shares of NASDAQ AUPH opened at $16.37 on Friday. The company has a current ratio of 5.55, a quick ratio of 5.01 and a debt-to-equity ratio of 0.08. Aurinia Pharmaceuticals Inc has a twelve month low of $7.28 and a twelve month high of $16.88. The stock has a 50 day moving average of $15.60 and a two-hundred day moving average of $15.26. The stock has a market cap of $2.11 billion, a P/E ratio of 7.54 and a beta of 1.41.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last issued its quarterly earnings data on Thursday, May 7th. The biotechnology company reported $0.25 earnings per share for the quarter, beating analysts’ consensus estimates of $0.18 by $0.07. Aurinia Pharmaceuticals had a return on equity of 26.62% and a net margin of 99.97%.The company had revenue of $77.71 million during the quarter, compared to analysts’ expectations of $76.98 million. On average, research analysts forecast that Aurinia Pharmaceuticals Inc will post 0.82 earnings per share for the current year.

Institutional Investors Weigh In On Aurinia Pharmaceuticals

Several large investors have recently modified their holdings of the stock. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Aurinia Pharmaceuticals by 25.9% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,407 shares of the biotechnology company’s stock worth $102,000 after purchasing an additional 1,318 shares during the last quarter. MML Investors Services LLC raised its stake in shares of Aurinia Pharmaceuticals by 12.7% during the fourth quarter. MML Investors Services LLC now owns 15,643 shares of the biotechnology company’s stock worth $250,000 after purchasing an additional 1,765 shares during the last quarter. First Trust Advisors LP raised its stake in shares of Aurinia Pharmaceuticals by 15.5% during the first quarter. First Trust Advisors LP now owns 14,065 shares of the biotechnology company’s stock worth $208,000 after purchasing an additional 1,883 shares during the last quarter. BOK Financial Private Wealth Inc. purchased a new stake in shares of Aurinia Pharmaceuticals during the fourth quarter worth approximately $32,000. Finally, Concurrent Investment Advisors LLC raised its stake in shares of Aurinia Pharmaceuticals by 7.8% during the fourth quarter. Concurrent Investment Advisors LLC now owns 30,270 shares of the biotechnology company’s stock worth $483,000 after purchasing an additional 2,200 shares during the last quarter. Hedge funds and other institutional investors own 36.83% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings cut Aurinia Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Friday, May 15th. Two investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $17.25.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases. The company’s proprietary molecule, voclosporin, is designed to selectively inhibit calcineurin and reduce inflammation associated with autoimmune responses. Aurinia operates research and development facilities in Canada and the United States, leveraging collaborations with academic institutions and contract research organizations to advance its clinical pipeline.

The company’s lead product, voclosporin (marketed as LUPKYNIS), received approval from the U.S.